When GLP-1 Medications Don't Go as Planned: Understanding…

When GLP-1 Medications Don't Go as Planned: Understanding Gastrointestinal Side Effects Growing Use of Weight-Loss Drugs Highlights the Importance of Individualized Treatment Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the treatment landscape for obesity and type 2 diabetes. Medications such as semaglutide and tirzepatide have demonstrated substantial benefits in weight reduction, glycemic control, cardiovascular risk reduction, and metabolic health. However, as the use of these therapies expands, clinicians are increasingly recognizing that patient experiences can vary considerably. While many individuals tolerate treatment well, others may develop significant gastrointestinal side effects that affect quality of life and treatment adherence. GLP-1 receptor agonists work by mimicking a naturally occurring hormone involved in appetite regulation and glucose metabolism. These medications: * Slow gastric emptying * Increase feelings of fullness * Reduce appetite * Improve insulin secretion * Lower post-meal glucose spikes While these mechanisms contribute to weight loss and metabolic benefits, they can also affect the digestive system. Common gastrointestinal symptoms include: * Nausea * Bloating * Abdominal discomfort *